The previous page is sending you to https://www.businesswire.com/news/home/20190329005556/en/FDA-Approves-TUDORZA%C2%AE-PRESSAIR%C2%AE-aclidinium-bromide-inhalation-powder-Supplemental-New-Drug-Application-sNDA-to-include-data-for-the-Reduction-of-COPD-Exacerbations-and-Hospitalizations.

 If you do not want to visit that page, you can return to the previous page.